Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Short term Debt (2017 - 2023)

Historic Short term Debt for Sutro Biopharma (STRO) over the last 6 years, with Q4 2023 value amounting to $4.1 million.

  • Sutro Biopharma's Short term Debt fell 6751.2% to $4.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $4.1 million, marking a year-over-year decrease of 6751.2%. This contributed to the annual value of $4.1 million for FY2023, which is 6751.2% down from last year.
  • Latest data reveals that Sutro Biopharma reported Short term Debt of $4.1 million as of Q4 2023, which was down 6751.2% from $7.1 million recorded in Q3 2023.
  • Over the past 5 years, Sutro Biopharma's Short term Debt peaked at $13.2 million during Q1 2023, and registered a low of $1.0 million during Q4 2019.
  • In the last 4 years, Sutro Biopharma's Short term Debt had a median value of $7.1 million in 2023 and averaged $8.1 million.
  • In the last 5 years, Sutro Biopharma's Short term Debt tumbled by 7883.15% in 2019 and then surged by 30000.0% in 2022.
  • Quarter analysis of 4 years shows Sutro Biopharma's Short term Debt stood at $1.0 million in 2019, then skyrocketed by 837.5% to $9.4 million in 2021, then surged by 33.33% to $12.5 million in 2022, then crashed by 67.51% to $4.1 million in 2023.
  • Its Short term Debt stands at $4.1 million for Q4 2023, versus $7.1 million for Q3 2023 and $10.2 million for Q2 2023.